Device Trial Radar · NCT06682923
MolecuLightDX Measurement Feature Clinical Validation
Last checked: Nov 20, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
34
Actual
Start
Oct 23, 2024
Primary completion
Feb 20, 2025
Study completion Feb 20, 2025
Sponsor
- Lead sponsor
- MolecuLight Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Nov 12, 2024
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, single-arm, paired clinical evaluation of the MolecuLightDX device in the measurement of surface wounds in patients.
Conditions
- Wounds
- Wound of Skin
Interventions
MolecuLight DX Imaging DeviceDevice
The MolecuLight DX Imaging Device is a fluorescence imaging device intended to acquire images from wounds. This will not alter the participant's standard of care treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean and SD of percent error for wound area by the MLI device in manual and automatic modes and by rulerTime frame: up to 6 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The Mayer Institute
Hamilton, Ontario, Canada
Judy Dan Centre for Hyperbaric Medicine & Advance Wound Care
North York, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.